Pharming (PHAR) Total Liabilities (2019 - 2026)
Pharming's (PHAR) quarterly Total Liabilities came in at $468.0 million in Q2 2026, up 4.87% YoY from $446.3 million in Q2 2025, and down 4.37% on a QoQ basis from $489.4 million in Q1 2026.
Pharming (PHAR) Total Liabilities (2019 - 2026) Analysis & Trends
Pharming (PHAR) has 8 years of Total Liabilities data on file, last reported at $468.0 million in Q2 2026.
- Quarterly Total Liabilities rose 4.87% year-over-year to $468.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $468.0 million (up 4.87% YoY) and the FY2025 annual result came in at $500.0 million, up 25.0% from the prior year.
- Total Liabilities slipped to $468.0 million in Q2 2026, from $489.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $382.3 billion in Q3 2022 to a low of $392.8 million in Q1 2022.
- A 5-year average of $22.9 billion and a median of $436.5 million in 2023 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 95256.66% in 2022, down 99.91% in 2022.
- Tracing PHAR's Total Liabilities over 5 years: stood at $382.3 billion in 2022, then plunged by 99.88% to $462.9 million in 2023, then declined by 13.58% to $400.0 million in 2024, then advanced by 25.0% to $500.0 million in 2025, then fell by 6.4% to $468.0 million in 2026.
- The last three Total Liabilities figures came in at $468.0 million (Q2 2026), $489.4 million (Q1 2026), and $500.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | 467.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 467.98 Mn |
| Mar 31, 2026 | 489.37 Mn |
| Dec 31, 2025 | 499.96 Mn |
| Sep 30, 2025 | 473.79 Mn |
| Jun 30, 2025 | 446.26 Mn |
| Mar 31, 2025 | 403.18 Mn |
| Dec 31, 2024 | 399.99 Mn |
| Sep 30, 2024 | 425.51 Mn |
| Jun 30, 2024 | 415.93 Mn |
| Mar 31, 2024 | 441.67 Mn |
| Dec 31, 2023 | 462.85 Mn |
| Sep 30, 2023 | 436.47 Mn |
| Jun 30, 2023 | 429.81 Mn |
| Mar 31, 2023 | 423.00 Mn |
| Sep 30, 2022 | 382.32 Bn |
| Jun 30, 2022 | 393.90 Mn |
| Mar 31, 2022 | 392.80 Mn |
| Dec 31, 2021 | 401,021.30 |
| Sep 30, 2021 | 400.94 Mn |
| Jun 30, 2021 | 411.84 Mn |